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Abstract
Background: Despite concerns about dolutegravir use in pregnancy, most low- and middle-income countries are
accelerating the introduction of dolutegravir-based regimens into national antiretroviral treatment programmes.
Questions remain about the acceptability of dolutegravir use in women due to the potential risks in pregnancy.
This study from South Africa and Uganda explored community values, preferences and attitudes towards the use of
dolutegravir-based regimens in women.
Methods: This study employed a qualitative design involving in-depth interviews and focus group discussion
conducted between August 2018 to March 2019. The study was conducted in the months following an
announcement of a potential risk for neural tube defects with dolutegravir use among women during conception
and the first trimester. Participants included HIV positive pregnant and lactating women and their partners. They
were selected purposively from urban poor communities in South Africa and Uganda. Data was analysed
thematically in NVivo.
Results: Forty-four in-depth interviews and 15 focus group discussions were conducted. Most participants had
positive views of dolutegravir-based regimens and perceived it to be more desirable compared with efavirenz-
containing regimens. There was widespread concern about use of dolutegravir during pregnancy and among
women of childbearing age due to publicity around the possible association with neural tube defects. Acceptability
was gendered, with nearly all male participants preferring their female spouses of childbearing potential not to use
dolutegravir, while most women not planning pregnancy wanted access to contraception alongside dolutegravir.
Community awareness and knowledge of dolutegravir was low and characterised by negative information. Women
were concerned about HIV-related stigma and wanted the privacy features of dolutegravir to be strengthened with
modification of the pill appearance and disguised packaging.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Yussif.alhassan@lstmed.ac.uk
1Community Health Systems Group, Department of International Public
Health, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3
5QA, UK
Full list of author information is available at the end of the article
Alhassan et al. BMC Public Health         (2020) 20:1883 
https://doi.org/10.1186/s12889-020-09991-w
(Continued from previous page)
Conclusions: Dolutegravir-based regimens were found to be generally acceptable for use in women except during
pregnancy. Interest in a dolutegravir-based regimen was linked with its perceived potential to enhance health,
privacy and reduce stigma while concerns about neural tube defects were the main potential barrier to
dolutegravir uptake in women. In order to optimise the community acceptability and uptake of acceptability-based
regimen among women it is critical to strengthen community awareness and understanding of dolutegravir
treatment, improve contraception services alongside the introduction of dolutegravir, and engage with male
partners.
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Background
Since 2016 many low– and middle -income countries
(LMICs) have accelerated the transition to dolutegravir-
based first-line HIV treatment regimens and away from
non-nucleoside reverse-transcriptase inhibitors (NNRT
Is) such as efavirenz and nevirapine. The World Health
Organisation (WHO), in guidelines released in 2016 [1]
and 2018 [2], encouraged countries with levels of pre-
treatment resistance to NNRTIs above 10% to consider
switching to an alternative antiretroviral (ARV) drug [3].
Dolutegravir is linked with greater viral suppression than
efavirenz [2], lower risks of drug-drug interactions [4]
and lower risk of emergence of drug resistance muta-
tions [5–7]. Programmatically, large-scale rollout of
dolutegravir-based regimen means increased ART har-
monisation, simplified drug procurement and lowering
of ART costs [2]. Recent modelling studies indicate
overall public health benefits from wider dolutegravir
use in terms of reduced deaths among women, de-
creased HIV transmission and disability-adjusted life
years [8, 9].
In May 2018, preliminary results from the Tsepamo
study in Botswana indicated a higher risk for neural
tube defects (NTDs) in infants born to women living
with HIV who conceived while taking dolutegravir
when compared to infants born to women receiving
efavirenz (4 in 426 infants; 0.94% vs 3 in 5787 infants;
0.05%) [10, 11]. Following this, the WHO released in-
terim guidelines recommending a cautious approach
to dolutegravir use in women peri-conception [12].
Dolutegravir use was discouraged unless women of
reproductive potential were using effective contracep-
tion or already in the second or third trimesters of
pregnancy [2]. In July 2019, WHO guidance was up-
dated to recommend dolutegravir as the preferred
first-line regimen for all women provided they had re-
ceived sufficient information on potential risks, bene-
fits and contraceptive options to make an informed
choice [13]. Revised recommendations were informed
by updated data from the Tsepamo study which re-
vealed a substantially lower, but still not insignificant,
risk for NTDs than originally reported (0.3%) [14].
By mid-2019, 123 LMICs had either adopted or were
planning to switch to dolutegravir-based regimens for
first line treatment in their national ART programmes
[15]. It is forecasted that by 2021 approximately 15 mil-
lion people would be using dolutegravir-based regimens
with efavirenz-containing regimens being replaced [16].
In Uganda, after a pilot in late 2017, the national roll-
out of dolutegravir-based regimens commenced in
March 2018 with access initially restricted among
women of childbearing potential but later extended to
include all adults in line with new WHO guidelines [17].
In the yet to be implemented South African guidelines
published in October 2019, dolutegravir is recom-
mended as the preferred regimen for all adults except in
women around the time of conception and in the first
trimester of pregnancy. Women of childbearing potential
are encouraged to use contraception if taking dolutegra-
vir [18].
As LMICs roll-out dolutegravir-based regimens in
their HIV treatment programmes, a key question is how
communities perceive the risks and benefits of the tran-
sition. The potential risks of dolutegravir in pregnancy
could profoundly influence community acceptability and
attitudes towards its use in women of childbearing age
[19]. Women may lack accessible information and ser-
vices and may face difficulties in decision-making despite
WHO guidelines emphasising individual choice. Pub-
lished studies are predominantly survey-based and pro-
vide limited data to predict community behaviour [2,
16]. Since dolutegravir is new with potential risks of use
in pregnancy, information on the values, preferences and
attitude of women and their male partners towards the
drug would be useful in informing appropriate program
and policy decisions to facilitate rollout among women.
We set out to explore community acceptability of
dolutegravir use in women, including potential barriers
to uptake related to community understandings, to
knowledge of side effects in pregnancy and to the atti-
tudes, values and preferences of women and their male
partners. This qualitative study was a component of
DolPHIN-2, a randomised controlled trial (NCT03249181)
conducted in Uganda and South Africa that found that
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dolutegravir is well-tolerated and achieves superior viro-
logical suppression compared to efavirenz (the standard
first-line HIV drug for pregnant women in both countries)
when initiated in women presenting late in pregnancy [20].
Methods
Study design
A descriptive qualitative design was used to better
understand participants’ perspectives on the acceptability
of the use of dolutegravir-based treatment among
women (including attitudes, preferences and values
about the drug) and the context in which those perspec-
tives are situated [21]. In-depth-interviews (IDIs) and
focus group discussions (FGDs) were used to gain in-
sights into individual and community perspectives for
data triangulation purposes [22]. Data collection was
staggered to allow for key findings discovered in the IDIs
to be explored further and validated in the FGDs. The
Standards for Reporting Qualitative Research were
employed to prepare this manuscript to ensure greater
transparency [23].
Study settings
In South Africa, participants were recruited from Gugu-
lethu, a peri-urban township in Western Cape with ap-
proximately 98,500 people [24]. The area is
economically deprived with a high level of HIV among
women, estimated at 18.9% in 2015 [25]. Participants in
Uganda were selected from poor urban communities in
and around Kampala, with HIV prevalence of around
6.9% [26]. Both settings had high background rates of
violence against women and girls, which may have con-
tributed to a disproportionately higher HIV infection
among women [27, 28].
Study population and participant selection
The study population included HIV-positive pregnant or
lactating women 18 years and older and their partners.
We included DolPHIN-2 trial participants initiated on
dolutegravir-based ART at presentation in the third tri-
mester of pregnancy. In Uganda, we also included non-
trial participants who had previously used dolutegravir
after participating in the pilot programme. The
dolutegravir-experienced participants were needed to
better understand their experience of the drug. Women
who were still on efavirenz regimen and had never used
dolutegravir, were included to learn about their under-
standing of the new treatment and male partner per-
spectives were included to help understand treatment
decision making in patriarchal societies [29].
Purposive sampling approach was applied to select the
study participants [30]. They were selected from
DolPHIN-2 affiliated health facilities, which provided
antenatal and postnatal care and/or ART services,
including the Infectious Disease Institute and the Kasan-
gati Health Centre in Uganda and Gugulethu Maternity
and Obstetric Unit in South Africa. Health workers
identified eligible women and referred them to research
assistants (RAs) who used a participant screening check-
list to verify eligibility. Eligible women were invited to
participate in the study; they chose which data collection
method they preferred (IDI or FGD); and a suitable date
and venue was agreed. All the IDIs and FGDs were con-
ducted in convenient and safe locations within the facil-
ities and community centres where the participants were
recruited.
An initial quota of 15 IDIs with women and 3 FGDs
with men and women in each study country were ini-
tially set with actual sample size determined by data sat-
uration. Participants were recruited and data collected
until all aspects of the research question were suffi-
ciently explored and new data were redundant [31]. Data
saturation was recognised through daily debriefing in-
volving the wider research team. No further participant
recruitment was needed after the data were analysed.
Data collection
Data were collected by RAs between August 2018 –
March 2019. Both male and female RAs experienced in
qualitative data collection were selected from the local
community as they spoke the local languages and under-
stood the social and cultural contexts of the study. Se-
lected RAs were given further training in the study
protocol and research ethics, including confidentiality
and consent administration. Data collection was carried
out around the time of the release of the initial results of
the Tsepamo study [21] and the WHO safety alert [22],
which may have shaped some participants’ awareness
and views on the subject as well as their willingness to
participate in the study. Neither study country had
started rolling out dolutegravir-based regimens in the
wider health system at the time of data collection.
Data collection was staggered to allow for emerging
results from IDIs to be validated during subsequent
FGDs. IDIs were carried out with women as they were
the primary respondents for the study. FGDs were con-
ducted with both men and women and were organised
separately for the different genders so that participants
could share their views freely. The IDIs and FGDs in-
volving women were carried out by female RAs. Each
FGD included 6–12 participants and was conducted by
two RAs, with one moderating and the other taking
notes. Interviews were conducted in Xhosa in South Af-
rica and Luganda in Uganda in safe and private locations
within facilities (IDIs) and community centres (FGDs).
Each IDI and FGD lasted for approximately 1 h, was
audio-recorded and complemented by written notes.
Topic guides were developed based on Sekhon et al.’s
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framework of acceptability [32] and the WHO 2018
ART guidelines [2], and included knowledge and aware-
ness, perceived benefits and risks, barriers to uptake of
and attitudes towards dolutegravir-based treatment. As
the study countries had not yet revised their guidelines,
hypothetical scenarios were incorporated into the topic
guides to give participants a sense of how dolutegravir
may be used among women of childbearing potential.
These were intended to encourage participants to think
deeply and accurately about the topic rather than obtain
quantifiable results. Topic guides were piloted and re-
vised iteratively as the data collection evolved. The daily
debriefings allowed for regular review and revision of
the topic guides.
Data analysis
Audio recordings were transcribed verbatim and trans-
lated into English by independent professionals. Data
verification for accuracy and completeness was done
through review of the transcripts by the RAs. Data were
analysed in NVivo 12 software based on a thematic ap-
proach [33]. A common coding framework was induct-
ively developed to facilitate inter-country comparison of
the data. In order to do this, 10% of the transcripts from
each context were initially reviewed by two researchers
(YA and AT) for recurring themes to develop independ-
ent coding lists; these were compared and merged; con-
sensus was sought for variations in coding [34]. The
framework was developed with flexibility to accommo-
date emergent new themes as coding evolved. Using the
framework, each transcript was read and reread for re-
current ideas. Codes were assigned to relevant segments
of the text; similar codes were aggregated to form
themes that were then used to address the research
questions and develop coherent narratives [35]. Contra-
dictory data identified during the analysis were initially
treated as potential different viewpoints; they were sub-
jected to further analyses to validate or refute them; vali-
dated data were used to enrich insights on the issue
[36]. To ensure rigor and trustworthiness, transcripts
were independently coded, compared and discussed [33].
Respondent validation was ensured by presenting an
anonymised summary of the Uganda findings to a com-
munity advisory group in Uganda (which included some
study participants) with subsequent feedback integrated
into the analysis. Emerging findings from the analysis
were discussed among the authors in regular qualitative
research network meetings.
Results
A total of 44 IDIs and 15 FGDs were carried out. Partici-
pation in the study was high; only 3% of eligible individ-
uals invited failed to participate, with time constraints
given as the main reason. Participants characteristics are
shown in Table 1. Very few participants had post-
secondary education, typical of the population from
whom we recruited. Results are presented under seven
major themes: awareness and knowledge; attitude to-
wards dolutegravir-based treatment; concerns about side
effects; autonomy and choice; contraception availability;
preferred ARV attributes; and community engagement.
Illustrative quotes from the data are presented in Table 2
and signposted with numbers in squared brackets] in the
text.
Awareness and knowledge
A minority of participants (19 of 42 interviewees) across
the two study countries had heard of dolutegravir and
the impending transition prior to the study. Most of
these were DolPHIN-2 trial participants; others had
heard from their peers and social media. No participant
reported hearing about dolutegravir on the news, radio
or a community programme. They noted similarity with
a previous antiretroviral transition in which they relied
mostly on informal channels to learn about the new
drug.
Nearly all the participants who had heard of dolutegra-
vir said their knowledge of the drug was inadequate and
Table 1 Participant characteristics
South Africa Uganda
In-depth interviews N = 20 N = 22
Pregnant 15 9
Lactating woman 5 13
Age range
18–24 years 3 2
> 24 years 17 20
Education
Primary 6 10
Secondary/High school 13 8
Post-secondary 1 2
Dolutegravir exposure
Exposed 8 11
Not exposed 12 11
Participant type
DolPHIN-2 trial participants 8 10
Non-trial participants 12 12
Focus group discussions N = 9 N = 6
Gender
Women 4 (40 participants) 3 (27 participants)
Men 5 (59 participants) 3 (28 participants)
Age range
18–24 years 18 10
> 24 years 81 45
Alhassan et al. BMC Public Health         (2020) 20:1883 Page 4 of 12
Ta
b
le
2
ke
y
th
em
es
in
th
e
in
te
rv
ie
w
s
an
d
fo
cu
s
gr
ou
p
di
sc
us
si
on
s
Th
em
es
Ill
us
tr
at
iv
e
q
uo
te
s
A
w
ar
en
es
s
an
d
kn
ow
le
dg
e
[1
]
“I
ha
ve
he
ar
d
ab
ou
t
it
be
fo
re
…
.[
bu
t]
Id
on
’t
ha
ve
a
lo
t
of
in
fo
rm
at
io
n
…
th
ey
ne
ed
to
ex
pl
ai
n
to
us
th
e
de
ta
ils
.…
w
ha
t
ki
nd
of
pi
ll
it
is,
ho
w
it
w
or
ks
an
d
w
ha
t
it
do
es
to
pr
eg
na
nt
w
om
en
”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P1
91
)
[2
]
“T
he
y
sh
ou
ld
or
ga
ni
se
w
or
ks
ho
ps
in
th
e
co
m
m
un
ity
to
te
ac
h
us
w
ith
ou
t
di
sc
rim
in
at
in
g
th
at
th
is
on
e
ha
s
th
e
vi
ru
s
th
is
on
e
do
es
n’
t
ha
ve
”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
05
)
A
tt
itu
de
to
w
ar
ds
do
lu
te
gr
av
ir-
ba
se
d
tr
ea
tm
en
t
[1
]
“d
ol
ut
eg
ra
vi
r
is
on
e
pi
ll
so
Ia
m
su
re
yo
u
w
ill
be
ab
le
to
ta
ke
it
on
ce
da
ily
,w
hi
le
th
e
AZ
Ts
w
er
e
tw
o
an
d
yo
u
w
er
e
su
pp
os
ed
to
us
e
it
ev
er
y
4
h.
Il
ik
e
it
[d
ol
ut
eg
ra
vi
r]
be
ca
us
e
of
th
at
”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P1
01
).
[2
]
“P
eo
pl
e
lo
se
ho
pe
w
he
n
th
ey
ar
e
in
fe
ct
ed
w
ith
th
is
di
se
as
e.
Th
ey
sa
y
yo
u
ar
e
de
ad
;y
ou
’re
fin
ish
ed
w
he
n
yo
u
ha
ve
H
IV
.B
ut
th
is
m
ed
ic
in
e
gi
ve
s
us
ho
pe
…
.I
t
w
ill
re
m
ov
e
th
at
th
ou
gh
t
th
at
th
e
ta
bl
et
s
ar
e
un
be
ar
ab
le
,t
ha
t
yo
u
ha
ve
H
IV
...
Yo
u
ta
ke
it
an
d
no
bo
dy
w
ill
kn
ow
th
at
yo
u
ha
ve
ta
ke
n
it.
N
ob
od
y
w
ill
kn
ow
yo
u
ar
e
H
IV
po
sit
iv
e.
”
(U
ga
nd
a,
W
om
en
’s
FG
D
29
7,
P6
).
[3
]
“I
ta
ke
th
e
m
ed
ic
in
e
to
he
lp
th
e
ba
by
an
d
m
e,
an
d
th
ey
sa
y
it
ca
n
af
fe
ct
th
e
ba
by
.I
am
w
or
rie
d.
Th
e
ol
d
on
e
[e
fa
vi
re
nz
]
af
fe
ct
s
us
a
lo
t
[d
ur
in
g
pr
eg
na
nc
y]
bu
t
I
w
ill
us
e
it
be
ca
us
e
it
do
es
n’
t
ha
ve
th
at
pr
ob
le
m
[N
TD
s]
.I
do
n’
t
w
an
t
an
yt
hi
ng
to
af
fe
ct
m
y
ba
by
.”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
04
)
[4
]
“I
w
ou
ld
no
t
al
lo
w
it
…
.u
nl
es
s
w
e
ha
d
a
ch
ild
be
fo
re
w
e
be
ca
m
e
H
IV
po
sit
iv
e.
If
w
e
do
n’
t
ha
ve
a
ch
ild
,I
w
ou
ld
no
t
al
lo
w
it
be
ca
us
e
Is
til
lw
an
t
to
ha
ve
a
ch
ild
.
…
It
do
es
n’
t
m
at
te
r
w
he
n
sh
e
us
es
it,
it
ca
n
st
ill
af
fe
ct
th
e
ba
by
.I
t
is
be
tt
er
sh
e
co
nt
in
ue
s
to
us
e
th
e
ol
d
on
e
[e
fa
vi
re
nz
].”
(S
ou
th
A
fri
ca
,M
en
’s
FG
D
19
8,
P9
)
[5
]
“T
he
y
ex
pl
ai
ne
d
to
m
e
ev
er
yt
hi
ng
[in
cl
ud
in
g
th
e
ris
ks
of
N
TD
],
bu
t
Is
ai
d
it
is
ok
be
ca
us
e
th
e
ba
by
w
as
al
re
ad
y
in
da
ng
er
.I
di
d
no
t
bo
ok
ea
rly
,a
nd
th
ey
sa
id
th
e
ba
by
m
ay
be
in
fe
ct
ed
.B
ut
w
ith
do
lu
te
gr
av
ir
th
er
e
is
a
ch
an
ce
…
.T
ha
t
is
w
hy
It
oo
k
it
…
to
pr
ot
ec
t
th
e
ba
by
…
.”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P1
03
).
C
on
ce
rn
s
ab
ou
t
si
de
ef
fe
ct
s
[1
]
“It
is
go
od
,b
ec
au
se
it
gi
ve
s
yo
u
ap
pe
tit
e,
yo
u
do
n’
t
ge
t
di
zz
y.
Yo
u
ca
n
st
ill
m
ov
e
w
he
n
yo
u
sw
al
lo
w
it.
Bu
t
th
e
ot
he
r
on
es
w
e
ha
d
be
fo
re
w
he
n
yo
u
sw
al
lo
w
th
em
yo
u
ha
ve
to
fir
st
st
ay
qu
ie
t
so
m
ew
he
re
.T
he
on
ly
pr
ob
le
m
w
as
th
at
at
th
e
be
gi
nn
in
g
Ic
ou
ld
no
t
sle
ep
w
el
l,
bu
t
it
is
ok
”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
95
)
[2
]
“It
ch
an
ge
d
m
y
w
ay
s
es
pe
ci
al
ly
m
y
fe
m
al
e
ho
rm
on
es
.W
he
n
Ia
m
w
ith
a
m
an
,I
do
n’
t
fe
el
it.
So
m
et
im
es
it
ta
ke
s
m
e
ba
ck
to
m
y
pe
rio
ds
an
d
Ig
et
th
em
ag
ai
n
…
”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
08
)
[3
]
“Y
es
[I
w
ill
ac
ce
pt
do
lu
te
gr
av
ir]
,a
s
lo
ng
as
it
ha
s
no
ne
ga
tiv
e
ef
fe
ct
,w
ea
ke
ni
ng
m
y
bo
dy
w
hi
le
pr
eg
na
nt
,c
au
sin
g
m
e
no
t
to
ea
t,
re
m
em
be
r
th
e
ch
ild
ne
ed
s
to
ea
t.”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
01
)
[4
]
“T
he
y
sh
ou
ld
do
pr
op
er
re
se
ar
ch
th
is
tim
e
…
th
ey
sh
ou
ld
m
ak
e
su
re
th
es
e
sid
e
ef
fe
ct
s
w
e
ar
e
af
ra
id
of
w
ill
no
t
be
th
er
e
…
.”
(S
ou
th
A
fri
ca
,W
om
en
’s
FG
D
19
3,
P5
)
[5
]
“I
w
ill
no
t
al
lo
w
it
be
ca
us
e
sh
e
w
ou
ld
be
ta
ki
ng
a
pi
ll
w
ho
se
sid
e
ef
fe
ct
s,
w
e
do
n’
t
kn
ow
…
.t
he
y
sh
ou
ld
do
m
or
e
re
se
ar
ch
be
fo
re
w
e
al
lo
w
ou
r
w
iv
es
to
us
e
it”
(S
ou
th
A
fri
ca
,M
en
’s
FG
D
19
8,
P2
)
[6
]
“I
w
ill
no
t
lik
e
th
at
be
ca
us
e
Ia
m
us
ed
to
th
is
pi
ll
an
d
Id
on
’t
kn
ow
ho
w
th
e
ot
he
r
pi
ll
w
ill
tr
ea
t
m
e.
It
to
ok
m
e
so
lo
ng
to
ge
t
us
e
to
th
is
on
e
[e
fa
vi
re
nz
-b
as
ed
re
gi
m
en
].”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P
11
1)
[7
]
“I
pe
rs
on
al
ly
,I
w
ou
ld
no
t
w
an
t
to
us
e
it
no
w
.B
ec
au
se
Ia
m
af
ra
id
th
at
th
ey
w
ill
m
ak
e
m
e
fa
t
an
d
le
av
e
m
e
w
ith
no
bu
tt
s
an
d
sk
in
ny
le
gs
....
Iw
ou
ld
w
an
t
to
se
e
ot
he
r
pe
op
le
us
e
it
fir
st
be
ca
us
e,
w
ha
t
if
it
do
es
so
m
et
hi
ng
th
at
is
irr
ev
er
sib
le
?”
(S
ou
th
A
fri
ca
,W
om
en
’s
FG
D
19
2,
P4
).
A
ut
on
om
y
an
d
ch
oi
ce
[1
]
“If
yo
u
fo
rc
e
m
e
to
us
e
th
at
m
ed
ic
in
e
an
d
Ig
et
an
y
pr
ob
le
m
it
m
ea
ns
Iw
ill
pu
t
th
e
bl
am
e
on
yo
u
so
it
w
ou
ld
be
be
tt
er
if
w
e
de
ci
de
fo
r
ou
rs
el
ve
s
…
.I
w
ill
fe
el
le
ss
pa
in
If
Id
ec
id
ed
to
us
e
it
an
d
ca
us
ed
pr
ob
le
m
s
…
.”
(U
ga
nd
a,
W
om
en
’s
FG
D
29
1,
P3
).
[2
]
“D
ec
id
in
g
on
th
ei
r
ow
n
w
ou
ld
be
go
od
…
.…
[B
ut
]
if
on
e
is
st
ill
gi
vi
ng
bi
rt
h,
th
ey
sh
ou
ld
no
t
be
gi
ve
n
th
at
ch
oi
ce
...
in
st
ea
d
of
de
ci
di
ng
fo
r
th
em
se
lv
es
,y
ou
[h
ea
lth
w
or
ke
rs
]
sh
ou
ld
m
ak
e
th
e
de
ci
sio
n
fo
r
th
em
.”
(S
ou
th
A
fri
ca
,M
en
’s
FG
D
19
9,
P6
)
[3
]
“I
m
ay
de
ci
de
on
m
y
ow
n
bu
t
Ih
av
e
m
ad
e
th
e
w
ro
ng
de
ci
sio
n
an
d
ye
t
it
w
ill
de
st
ro
y
m
y
he
al
th
.S
o,
it
is
go
od
to
fir
st
co
ns
ul
t
so
m
eo
ne
w
ho
is
be
tt
er
th
an
yo
u
…
th
e
he
al
th
w
or
ke
rs
”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
08
)
[4
]
“O
ur
liv
es
ar
e
in
yo
ur
ha
nd
s,
ba
sa
w
o
[h
ea
lth
w
or
ke
rs
].
Yo
u
kn
ow
be
tt
er
th
e
sid
e
ef
fe
ct
s.
It’
s
ha
rd
fo
r
us
or
di
na
ry
pe
op
le
to
de
ci
de
on
th
is
…
.I
fy
ou
sa
y
it
is
no
t
go
od
fo
r
us
pr
eg
na
nt
w
om
en
,w
e
w
ill
re
sp
ec
t
th
at
be
ca
us
e
w
e
kn
ow
yo
u
w
ill
m
ak
e
th
e
rig
ht
de
ci
sio
n
fo
r
us
.”
(U
ga
nd
a,
W
om
en
’s
FG
D
29
2,
P5
)
[5
]
“t
he
m
os
t
im
po
rt
an
t
th
in
g
is
ed
uc
at
in
g
us
m
or
e
ab
ou
t
th
is
dr
ug
[d
ol
ut
eg
ra
vi
r].
It’
s
im
po
rt
an
t
to
un
de
rs
ta
nd
ab
ou
t
th
at
dr
ug
to
av
oi
d
ex
cu
se
s
th
at
th
e
do
ct
or
di
d
no
t
ed
uc
at
e
m
e
th
at
is
w
hy
Im
ad
e
th
e
w
ro
ng
de
ci
sio
n.
If
Iu
nd
er
st
an
d
Iw
ill
m
ak
e
th
e
rig
ht
de
ci
sio
n.
”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
01
)
[6
]
“T
he
y
sh
ou
ld
fir
st
ex
pl
ai
n
it
to
us
,h
ow
it
w
ill
w
or
k
an
d
th
e
ris
ks
.…
th
ey
ne
ed
to
ex
pl
ai
n
it
fir
st
an
d
th
en
as
k
us
to
de
ci
de
.W
e
ar
e
ca
pa
bl
e
if
th
ey
he
lp
us
.”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P1
91
)
C
on
tr
ac
ep
tio
n
in
do
lu
te
gr
av
ir-
ba
se
d
tr
ea
tm
en
t
[1
]
“F
am
ily
pl
an
ni
ng
is
no
t
a
pr
ob
le
m
fo
r
m
e.
Iw
ill
do
it
so
Ic
an
al
so
us
e
th
e
ne
w
dr
ug
.…
fa
m
ily
pl
an
ni
ng
w
ill
he
lp
us
no
t
to
ha
ve
in
fe
ct
ed
ch
ild
re
n”
(S
ou
th
A
fri
ca
,
W
om
en
’s
ID
I,
P1
99
)
[2
]
“I
f
yo
u
gi
ve
bi
rt
h
ev
er
y
ye
ar
an
d
yo
u
ar
e
H
IV
+
,i
t
re
du
ce
s
yo
ur
he
al
th
.…
it
re
du
ce
s
yo
ur
lif
e
sp
an
.Y
ou
ne
ed
to
sp
ac
e
th
e
ch
ild
re
n
an
d
go
on
fa
m
ily
pl
an
ni
ng
…
.”
(U
ga
nd
a,
W
om
en
’s
ID
I,
P2
07
)
[3
]
“It
m
us
t
be
gi
ve
n
to
w
om
en
w
ho
fe
el
lik
e
th
ey
ha
ve
ha
d
en
ou
gh
ch
ild
re
n;
no
t
th
e
yo
un
g
on
es
be
ca
us
e
th
ey
st
ill
w
an
t
to
ge
t
m
ar
rie
d
an
d
ha
ve
fa
m
ily
.…
m
en
w
an
t
ch
ild
re
n
an
d
if
sh
e
ca
n’
t
pr
ov
id
e
th
at
th
er
e
w
ill
be
pr
ob
le
m
s
…
.”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P1
04
)
[4
]
“T
he
y
sh
ou
ld
gi
ve
us
on
e
th
at
yo
u
ca
n
ea
sil
y
ch
an
ge
so
th
at
if
yo
u
ch
an
ge
yo
ur
m
in
d
an
d
yo
u
w
an
t
to
ha
ve
ch
ild
re
n
yo
u
ca
n
st
op
.”
(S
ou
th
A
fri
ca
,w
om
en
’s
ID
I,
P2
07
)
Alhassan et al. BMC Public Health         (2020) 20:1883 Page 5 of 12
Ta
b
le
2
ke
y
th
em
es
in
th
e
in
te
rv
ie
w
s
an
d
fo
cu
s
gr
ou
p
di
sc
us
si
on
s
(C
on
tin
ue
d)
Th
em
es
Ill
us
tr
at
iv
e
q
uo
te
s
[5
]
“I
fe
el
lik
e
th
e
pe
op
le
th
at
ar
e
no
t
us
in
g
co
nt
ra
ce
pt
io
n,
es
pe
ci
al
ly
th
e
yo
un
ge
r
on
es
,w
ill
be
le
ft
be
hi
nd
.I
t
m
ea
ns
th
at
if
th
ey
w
an
t
to
ha
ve
ch
ild
re
n,
th
ey
w
ill
no
t
ta
ke
it.
”
(S
ou
th
A
fri
ca
,w
om
en
’s
ID
I,
P1
01
).
[6
]
“T
he
re
is
go
in
g
to
be
pr
ob
le
m
be
ca
us
e
so
m
et
im
es
yo
u
fin
d
on
e
w
ho
is
pr
eg
na
nt
,a
nd
sh
e
st
ill
go
es
fo
r
fa
m
ily
pl
an
ni
ng
.S
om
et
im
es
th
e
co
nt
ra
ce
pt
iv
e
w
ill
fa
il.
…
so
m
et
im
es
it
is
no
t
th
e
dr
ug
,i
t’s
th
e
w
om
an
,t
he
th
in
g
w
ill
ex
pi
re
bu
t
sh
e
w
ill
no
t
go
fo
r
ne
w
on
e.
…
so
m
et
im
es
it
is
th
e
cl
in
ic
,t
he
y
ke
ep
po
st
po
ni
ng
...”
(U
ga
nd
a,
W
om
en
’s
FG
D
29
1,
P7
)
Pr
ef
er
re
d
A
RV
fe
at
ur
es
[1
]
“W
ha
t
Ia
sk
[a
bo
ut
do
lu
te
gr
av
ir]
is
th
at
th
ey
sh
ou
ld
re
du
ce
th
e
ta
bl
et
an
d
co
nf
us
e
it
a
bi
t
w
ith
ev
er
yd
ay
dr
ug
s
so
th
at
w
he
n
so
m
eo
ne
lo
ok
s
at
it
th
ey
do
no
t
kn
ow
it,
th
ey
do
n’
t
no
tic
e
th
at
yo
u
ar
e
in
fe
ct
ed
.…
it
sh
ou
ld
be
a
sm
al
lt
ab
le
t
lik
e
Pa
na
do
l,
so
m
et
hi
ng
th
at
is
no
t
di
ffe
re
nt
…
.”
(U
ga
nd
a,
W
om
en
’s
FG
D
29
3,
P7
)
[2
]
“I
do
n’
t
lik
e
it,
it
m
ak
es
a
lo
t
of
no
ise
,i
t
is
no
isy
.I
t
is
ha
rd
to
ta
ke
it
in
pu
bl
ic
.I
ft
he
ne
w
on
e
[d
ol
ut
eg
ra
vi
r]
ca
n
be
m
ad
e
so
th
at
w
he
n
yo
u
pu
t
it
in
yo
ur
ba
g,
it
do
es
n’
t
m
ak
e
no
ise
.”
(S
ou
th
A
fri
ca
,W
om
en
’s
ID
I,
P1
13
)
[3
]
“I
th
in
k
it
[d
ol
ut
eg
ra
vi
r]
sh
ou
ld
be
sim
ila
r
to
th
e
in
je
ct
io
n
yo
u
ge
t
fro
m
th
e
fa
m
ily
pl
an
ni
ng
cl
in
ic
;y
ou
ge
t
on
ce
m
on
th
ly
.…
im
ag
in
e
if
yo
u
ha
ve
no
t
to
ld
yo
ur
pa
rt
ne
r,
he
w
ill
fin
d
ou
t
if
yo
u
ha
ve
th
re
e
dr
ug
s
ev
er
y
da
y”
(S
ou
th
A
fri
ca
,W
om
en
’s
FG
D
19
4,
P2
)
C
om
m
un
ity
en
ga
ge
m
en
t
[1
]
“W
e
ne
ed
to
ag
re
e
…
M
e
an
d
th
e
m
ot
he
r
of
th
e
ba
by
…
.A
nd
se
e
if
th
is
th
in
g
w
ill
no
t
…
be
ca
us
e
th
er
e
is
th
e
th
in
g
of
on
e
be
in
g
al
le
rg
ic
or
no
t
al
le
rg
ic
…
w
ill
th
is
th
in
g
be
ab
le
to
pr
ot
ec
t
un
til
…
w
e
ca
n
re
bu
ild
ou
r
fa
m
ily
(S
ou
th
A
fri
ca
,M
en
’s
FG
D
19
8,
P1
1)
.
Alhassan et al. BMC Public Health         (2020) 20:1883 Page 6 of 12
wanted to learn more [1]. Most were aware that dolute-
gravir is more effective than efavirenz and associated
with birth defects when used in pregnancy. Several of
them reported inaccurate information, saying dolutegra-
vir: “is an injectable”, “cures HIV”, “causes miscarriage”,
“is taken once a month” and “causes tumour in the
womb”. As data collection coincided with the release of
information on the safety signal, participants reported
uncertainty about the safety of dolutegravir. They men-
tioned the need for more information on risks, condi-
tions of use, contraindications and how to use
dolutegravir in pregnancy.
Participants suggested the need for a more inclusive
awareness-raising campaign that targets all community
members, including HIV positive and negatives. Trad-
itional outreaches that target only PLHIV were deemed
to stigmatise and deter people [2]. Although they identi-
fied TV, radio and social media (mostly mentioned in
South Africa) as important media for awareness cam-
paigns, they worried that they could lead to misinforma-
tion and, in the case of social media, exclude rural and
uneducated populations. They preferred community-
based communication interventions that allow for con-
tact with health professional to address their questions.
Additionally, women said they wanted to have more
contact time and dialogue with health workers during
treatment consultation.
Attitude towards dolutegravir-based treatment
Most participants had positive views of dolutegravir and
thought it was generally more desirable than efavirenz
because it provides quicker viral suppression, milder side
effects and has low pill burden [1]. Efavirenz-based regi-
mens, with their severe side effects, were perceived to be
stigmatising (both internalised and from the community)
and incapacitating. They noted that dolutegravir would
make HIV patients ‘look and feel normal’ to carry out
their daily activities and would encourage ART take up
and adherence [2].
However, some participants did have concerns about
dolutegravir use in pregnancy. Much of this was related
to the risk of NTDs. Following the WHO safety alert,
most dolutegravir messages centred around the risk of
birth defects, which caused stress and anxiety in the
community. Participants were extremely fearful of the
risk NTDs and unwilling to risk it for any benefit. Even
when it was explained to them that the risk of NTDs
was marginal and limited to the first trimester, most
(both men and women) were still sceptical. Some
women stated that although efavirenz treated them badly
during pregnancy (because it made them nauseous, etc)
they would rather use it than to risk birth defects with
dolutegravir [3]. Men appeared to be less likely to allow
their partners to use dolutegravir due to NTDs and a
belief that dolutegravir causes infertility among women
[4]. Pregnant women who initiated ART late in preg-
nancy appeared more likely to accept dolutegravir use in
pregnancy. Such participants were motivated by the
need to minimise the risk of vertical transmission [5].
Women were generally conscious about the lack of evi-
dence on the safety of dolutegravir, being a new drug,
and would rather continue to use efavirenz during preg-
nancy until dolutegravir has been ‘fully tested’ to estab-
lish its safety.
There were mixed views on dolutegravir use among
women of childbearing potential outside pregnancy.
Some participants, mostly men, believed that it was diffi-
cult for women to adhere to the conditions for safe
usage of dolutegravir (e.g. effective contraception) and
suggested that women of childbearing potential should
be prevented from using the drug altogether. Most of
those who wanted non-pregnant women to use dolute-
gravir often did not understand that NTDs were caused
during conception (and not in pregnancy). They were
mainly younger women, from South Africa, and had
confidence in their ability to control their fertility plans.
Concerns about side effects
Most participants who had used dolutegravir reported
no side effects, while a few had suffered insomnia, nau-
sea, weight gain and low sex drive [1, 2]. They noted that
the effects were relatively less severe compared with pre-
vious ARV drugs (e.g. efavirenz) and did not prevent
them from taking their pills properly [1]. Even though
they worried about side effects, they thought these were
acceptable because dolutegravir provides important ben-
efits. Overall, participants noted that it was important
for dolutegravir side effects to be mild, particularly for
pregnant women to use it as they are already burdened
by the effects of pregnancy and other medication.
Reflecting on previous ART drugs, they identified “loss
of appetite”, “bad dreams”, “dizziness”, “body weakness”
and visible symptoms such as rashes as some of the key
side effects that could discourage women from using
dolutegravir if it were to cause them [3].
Some women, mostly from South Africa, expressed
reservations about new ART drugs in general, and
dolutegravir by extension, and their potential to cause
unforeseen side effects. They worried about not knowing
the full range of the side effects of dolutegravir and
wanted it to be further “tested” [4, 5]. Some women
stated that they would rather “wait-and-see” how it
treats other people before deciding to use it [7]. Others
lamented over challenges with adjusting to new ART
drugs and feared this could discourage some women
from switching [6]. In South Africa, concern about
weight gain was widely mentioned amongst both male
and female participants as a potential barrier to
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dolutegravir use among women [7]. Only one participant
(female) in Uganda mentioned weight gain as a potential
issue with dolutegravir, suggesting it may not be as im-
portant in that country.
Autonomy and choice
Participants across both countries agreed on the need
for patient involvement in decisions on their ART. There
were varied views on whether and how women should
be given choice. For some women the desire for choice
was based on the need for control over their treatment
and fertility plans, to be able to come off dolutegravir
and conceive when they liked. Another key point made
was that given the seriousness of NTDs it was essential
for health workers to protect themselves by transferring
the responsibility of decision to women [1]. Some
women mentioned that they would feel less resentful if
they participated in deciding on their use of dolutegravir
that resulted in NTDs. Others stated that giving them
autonomy over dolutegravir would enable them take
greater responsibility for their treatment and improve
treatment adherence [1].
However, most male participants in both contexts and
women in Uganda thought it was risky to allow women
to decide on their use of dolutegravir, fearing that they
would make wrong choices [3]. They believed that health
workers were more capable of understanding the relative
benefits and risks of dolutegravir and trusted that they
would make the best decision for them [4]. Several
women in South Africa were confident that, given the
necessary information and support, they would be able
to make the right decision about their treatment.
Women across both countries were receptive to the idea
of shared decision-making on dolutegravir involving
health workers and patients. They indicated the need for
the former to provide information, counselling and sup-
port to enable the latter to evaluate available treatment
options and chose their preferred treatment [5, 6]. They
expressed the need for more information on the benefits
and risks of dolutegravir to enable them to make the
right decision [6].
Contraception in dolutegravir-based treatment
Response on the contraception requirement was varied,
with older women with children being more receptive to
practicing contraception in order to use dolutegravir.
Most women living with HIV (WLHIV) were concerned
about potential vertical transmission of HIV to their ba-
bies and thus welcome the contraception requirement
[1]. Some women perceived contraception as an oppor-
tunity to space pregnancy and recover their health after
the strain of childbirth on their immune system [2].
Most younger women feared that the contraception
requirement would hinder fertility plans, strain marriage
relations and undermine the prospects of marriage [3].
Some women perceived the contraception requirement
as an imposition of family planning on them. Whilst not
entirely disapproving of contraception, most women
were mainly concerned about the ‘long-acting’ element
of the contraception proposed by the WHO guidelines,
which was commonly misconstrued to mean permanent
contraception. Women expressed a desire for greater
control and over their fertility plans, and the need for
flexible contraception methods [4]. Another major con-
cern was that the contraception requirement would re-
strict dolutegravir use among most young women
because they desire to have children or lack access to ef-
fective contraceptives [5]. In Uganda several women re-
ported serious financial barriers to contraceptive use due
to lack of supply in public health facilities and the need
for them to purchase from private clinics. Some women
also lacked access due to the ARV drug they are using
and the associated contraindication with the available
contraceptives.
There was scepticism expressed over the extent of pro-
tection that contraception could provide against NTDs. A
key concern was about contraceptive failure leading to un-
planned pregnancies. Participants reported widespread
contraception adherence challenges among women across
both countries. In Uganda, women reported long delays in
the start of a new contraceptive after the expiration of an
older one as a potential cause of widespread unplanned
pregnancies during dolutegravir use [6].
Contraceptive preference varied between participants.
Older women appeared to prefer longer-term contracep-
tives such as intrauterine device, implant and sterilisa-
tion (in the case of South Africa) so that they do not
have to visit the facility regularly to renew. Younger
women also liked long-acting contraceptives due to the
convenience that they offer but preferred those that are
not too long term and permanent and are reversible. In
South Africa, they desired the contraceptive injection be-
cause it was also relatively less invasive, even though
they worried that it was being discontinued in the
country.
Participants across both countries appreciated the vari-
ations in the suitability of different contraceptive
methods among women and suggested the need for
health workers to assess women to help them identify
their most suitable methods. They also wanted women
to be actively involved in making decisions about their
contraception.
Preferred ARV attributes
Women identified key drug features that they believe
would improve the uptake and adherence to
dolutegravir-based treatment when it is introduced.
These were rooted in the need to keep their HIV status
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secret. Reflecting on previous ARV drugs, several women
said they wanted dolutegravir pill (e.g. shape, colour and
size) to be modified to look like ordinary drugs in the
community [1]. They noted that most of the standard
ARV drugs were easily identifiable with HIV which dis-
couraged many women from using them if they have not
disclosed their status. Women also preferred that the
package for dolutegravir is not marked with HIV identi-
fiers; ideally, they should be kept in a plain container
and padded to ensure that they do not rattle to draw at-
tention [2]. There was also a desire for injectables and
for dolutegravir regimen to be made into a single pill
that is taken once daily, weekly or monthly. They
thought that reducing the pill burden was essential to
decreasing the risk of inadvertent disclosure [3].
Community engagement
Participants expressed the need for policymakers and
programmes to actively engage with WLHIV in order to
understand their needs and address them in the rollout.
They also noted that the nature of dolutegravir, with its
potential teratogenic effects, would require collective de-
cision making between couples for women to use it.
Hence, they suggested the need for greater engagement
with men to ensure that they are fully informed about
dolutegravir. The men also expressed the need to facili-
tate dialogue between couples over the use of dolutegra-
vir among women [1].
Discussion
This qualitative study was the first to investigate the ac-
ceptability of dolutegravir use in WLHIV in Southern
and Eastern Africa. Participants found a dolutegravir-
based regimen to be desirable for first line HIV treat-
ment in women except during pregnancy. Concern
about the association of dolutegravir with NTDs was the
main reason for the reluctance to use dolutegravir in
pregnancy. Women were more accepting of dolutegravir
use in pregnancy if they are being initiated on ART later
in pregnancy. Acceptability was gendered, with nearly all
male participants preferring their female spouses of
childbearing potential not to use dolutegravir, while
most women not planning pregnancy wanted access to
contraception alongside dolutegravir. A shared decision-
making arrangement involving health workers and pa-
tients, with the former providing sufficient information,
counselling and support to enable the latter evaluate
available treatment options was identified as a fair ap-
proach upon which dolutegravir use among women
should be determined. Greater dialogue between spouses
was recommended to promote acceptability.
There are few previous studies in which to contextual-
ise our findings. Campbell et al. surveyed 636 ART naïve
and experienced patients from Uganda and Nigeria who
had been initiated on dolutegravir-based regimen in a
pilot study [37]. Overall, 90% of the patients reported
high acceptability of dolutegravir-based treatment, citing
improvement with fewer side effects as the main reason.
This level of acceptability appears to be higher than that
observed in our study, which may be partly because their
study was conducted prior to the NTD signal and partic-
ipants perspectives may not have been affected by such
serious adverse effects. However, Migone and Ghadrshe-
nas carried out a survey with representatives of networks
of women living with HIV in sub-Sahara Africa follow-
ing the signal to examine the acceptability of dolutegra-
vir use in women of childbearing potential [38].
Consistent with our findings, 37% (of 51 respondents)
approved and the rest disapproved or were unsure about
dolutegravir use among women of childbearing poten-
tial. They noted women placed high value on their au-
tonomy and preferred a choice in their ARV regimen.
With current evidence suggesting a lower risk of NTDs
with periconception use of dolutegravir [13, 14], it will
be interesting to see how this may have shifted commu-
nity attitudes and acceptability of the drug.
The main reasons for the interest in dolutegravir re-
lated to its efficacy and safety profile. With its milder
side-effects, participants associated dolutegravir with
providing greater confidentiality and privacy and miti-
gating unintended disclosure and internalised stigma.
They also noted that it offered hope due to its quick
viral suppression feature and will potentially improve
ART uptake and adherence. Similar psychosocial bene-
fits have been reported by Kerrigan et al. in relation to
patience preference for long-acting ART injectables in
US and Spain [39]. However, in South Africa and
Uganda, they demonstrate the salience of stigma in the
lives of WLHIV and the potential negative role this
could have on ART adherence [39–41]. Despite dolute-
gravir potentially minimising stigma, further structural
and biomedical interventions will continue to be needed
to accelerate ART uptake and adherence. As noted by
the participants, dolutegravir can further contribute to
the biomedical solution by strengthening its privacy fea-
tures with disguised pills appearance and packaging so
that they are not easily identifiable with HIV.
Several barriers to optimal acceptability of
dolutegravir-based treatment remain. They include con-
cern about dolutegravir related serious adverse events
such as NTDs and other ‘unknown risks’ due to it being
a new drug. Minor side effects such as insomnia and
nausea, while important, are less likely to have signifi-
cant negative effect on acceptability as there are per-
ceived to be ‘tolerable’ relative to the benefits that
dolutegravir offers. Although dolutegravir related weight
gain was identified as a potential barrier to acceptability
in South Africa, it is unclear what the implications might
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be in Uganda, and further research may be required.
The risk of NTDs was taken extremely seriously among
both the men and women participants and remains a
significant barrier to uptake of dolutegravir-based treat-
ment. The emerging evidence of a lesser risk of NTDs
with dolutegravir could alleviate individuals fears and
encourage acceptability but needs to be effectively com-
municated in communities. Moreover, the lack of
contraception services, especially in rural areas, and the
financial and logistical burden of contraception could
discourage many risk-averse women of childbearing age
from initiating on dolutegravir-based treatment. Patient
characteristics may also affect acceptability; for example,
ART experienced patients who are stable on their regi-
men expressed less interest for switching to
dolutegravir-based treatment as they are unsure about
how they will be treated by the potential side effects, and
younger women of childbearing potential with no/fewer
children were more hesitant towards dolutegravir due to
fear of teratogenicity.
The study found limited community awareness and
knowledge of dolutegravir-based treatment in South Af-
rica and Uganda. Not only were individuals not aware,
there was widespread negative information about dolute-
gravir which aggravated fears about the drug. Rollout of
dolutegravir-based regimen had not started in both
countries at the time of the study which may have con-
tributed to the low awareness, even though Uganda was
only a few months away. Crucially, the finding demon-
strates a weakness in information campaign strategies
for new ARV drugs in both countries which, as the par-
ticipants noted, were mainly facility- and patient- fo-
cused; community-based campaigns tend to alienate
many community members as they target only HIV
positive persons who fail to attend because of stigma.
With social networks operating as vital conduits for in-
formation and influence on new HIV treatments in
resource-limited settings [42, 43], a more inclusive
awareness campaign targeting wider community mem-
bers (including both positives and negatives) is needed
to accelerate information dissemination about dolutegra-
vir. Although traditional mass media such as radio and
television are widely recognised for their extensive reach,
participants expressed preference for community-based
communication interventions with contact with health
professional to raise awareness and educate about
dolutegravir. With widespread negative information and
uncertainty about dolutegravir at the community level,
individuals longed for dialogue with health professionals
in order to learn and seek answers to concerns they have
about dolutegravir. Such approach could be useful in al-
leviating community fears about dolutegravir use in
pregnancy. In a study in Philippines, Valido et al. found
that the use of community-based communications
interventions involving health workers increased com-
munity trust and confidence in a new vaccine that had
previously been marred in controversy [44].
Consistent with Chadambuka et al. [29], we found that
men were very influential in their spouses use of ART
and would be crucial to ensuring optimal uptake and ad-
herence to dolutegravir-based treatment among women,
particularly due to the potential teratogenicity and
contraception. This suggests the need for active engage-
ment with men to encourage women to adopt
dolutegravir-based treatment. Existing evidence indicates
that male partner involvement does have significant
positive impact on ART uptake among their spouses as
demonstrated in Zambia [45] and Nairobi [46]. Commu-
nity interventions promoting male partner involvement
in ART need to combine with partner disclosure initia-
tives to maximise their impact.
This study failed to produce conclusive insights into
women’s feelings about a potential dolutegravir related
weight gain. Future research needs to investigate the po-
tential association of dolutegravir with weight gain and
its implications on acceptability among women. More-
over, it would be interesting to examine the unintended
consequences of dolutegravir-based treatment, particu-
larly on early antenatal presentation and ART adherence.
With dolutegravir yielding rapid viral suppression, some
women may be motivated or discouraged to present
early for antenatal care. Research is also needed to ex-
plore optimal approaches to health worker-patient com-
munication of ART-related risks and choice.
Limitations
The study was carried out among pregnant and lactating
mothers and their partners, which may limit the general-
isation of the results to broader population of WLHIV.
Reported acceptability of dolutegravir may have been
confounded by some participants involvement in the
DolPHIN-2 clinical trial who were given more extensive
information and counselling than is normally the case in
health facilities. Further, participants were asked to re-
spond to several hypothetical scenarios about dolutegra-
vir use in pregnancy and among women of childbearing
potential based on limited information from the WHO
2018 guidelines. Since then new guidelines have been re-
leased by the WHO and the Ministries of Health in
South Africa and Uganda recommending dolutegravir
use in pregnancy and among women of childbearing po-
tential, which may influence attitudes toward the drug.
Unlike the DolPHIN-2 trial where participants were
given multiple-tablet dolutegravir-based regimen, a fixed
dose combination regimen will be used in the national
rollout, which may encourage greater acceptability. We
could not perform back-translation on the transcripts
that were translated from the local languages to English
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due to resource constraints; however, all the transcripts
were checked for accuracy and completeness by the RAs
to enhance the validity of the data.
Conclusions
This study found community desire for dolutegravir use
in first line HIV treatment among women due to its po-
tential to enhance health, privacy and reduce HIV-
related stigma. However, there is widespread anxiety and
reluctance towards dolutegravir use in women during
pregnancy due to its association with NTDs. Ensuring
optimal community acceptability requires strengthening
community awareness and understanding of
dolutegravir-based treatment with emphasis on increas-
ing the evidence-base on safety in pregnancy, effective
health worker-patient communication of ART related
risks, and alleviating concerns about risks in pregnancy.
Contraception services need to be improved, including
the availability of contraceptive options and integration
of contraception and HIV services. It is essential to en-
gage with women to understand their needs and address
them in the rollout of dolutegravir, and with men to gain
their cooperation and buy-in to women’s use of
dolutegravir.
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